Hemoglobin A<sub>1c</sub> Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
October 22, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
- Diabetic Kidney Disease: Clinical - 2
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
- Cherney, David, Toronto General Hospital, Toronto, Ontario, Canada
- Hadjadj, Samy, L'institut du thorax, INSERM CNRS, Univ Nantes, CHU Nantes, Nantes, France
- Idorn, Thomas, Novo Nordisk A/S, Søborg, Denmark
- Mosenzon, Ofri, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel
- Pilemann-Lyberg, Sascha, Novo Nordisk A/S, Søborg, Denmark
- Perkovic, Vlado, The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia
- Tuttle, Katherine R., Providence Medical Research Center, Providence Health Care, Spokane, Washington, United States
- Rasmussen, Soren, Novo Nordisk A/S, Søborg, Denmark
- Bain, Stephen C., Swansea University Medical School, Swansea Univeristy, Swansea, United Kingdom
Katherine R. Tuttle,
Stephen C. Bain,
Hyperglycemia is an established risk factor for the development and progression of chronic kidney disease. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes (T2D) across a wide range of estimated glomerular filtration rates (eGFRs). We investigated whether baseline eGFR affected glycated hemoglobin (HbA1c) reduction with semaglutide.
This post hoc, trial-level analysis considered all SUSTAIN (1–10) and PIONEER (1–10) trials where renal impairment was not an exclusion criteria and where the number of subjects receiving semaglutide with eGFR <60 mL/min/1.73m2 was >10. It included data for once-weekly subcutaneous semaglutide (SUSTAIN 4–6, pooled 0.5 and 1.0 mg; SUSTAIN 10, 1.0 mg only) and once-daily oral semaglutide (PIONEER 5 and 6, 14 mg); comparator data were not analyzed. Subjects receiving semaglutide were grouped by baseline eGFR; the eGFR subgroups evaluated were selected according to number of subjects meeting eGFR cut-offs (≥60 and <60 mL/min/1.73 m2 in SUSTAIN 4, 5, and 10; <45, 45 to <60 and ≥60 mL/min/1.73 m2 in SUSTAIN 6 and PIONEER 5 and 6). Within each trial, absolute estimated change in HbA1c from baseline to end of treatment (EOT) was compared between eGFR subgroups using a linear mixed model.
Mean HbA1c at baseline ranged from 7.9% to 8.7% across the subgroups. Semaglutide significantly reduced HbA1c at a comparable magnitude across eGFR subgroups in all trials (mean reduction of 1.0–1.7% from baseline to EOT; p>0.148 for difference between eGFR subgroups within each trial; Figure).
Semaglutide (subcutaneous and oral) is an effective glucose-lowering agent in subjects with T2D, independently of baseline eGFR, including in those with chronic kidney disease.
- Commercial Support